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Introduction.  
Chronic obstructive pulmonary disease is a weighty social health and economic 
importance, and remains one of the major causes of morbidity and mortality worldwide. 
Presently, special attention is paid to comorbid conditions, when the patient has a combination of 
pathology respiratory and cardiovascular systems. This research has been devoted to finding 
ways to optimize the treatment of moderate acute exacerbations of chronic obstructive 
pulmonary disease with the complication of bronchoectasis on the background of coronary heart 
disease. 
Keywords: obstructive bronchitis, bronchiectasis, coronary heart disease, glutoksim, L-
arginine. 
In the XX-XXI century there were accounts of sudden increase in the number of patients 
with chronic obstructive pulmonary disease (COPD). This pathology has now become of 
significant medical, social and economic importance, and remains one of the major causes of 
morbidity and mortality worldwide [7, 20]. Currently, according to WHO, COPD affects 0.8% of 
the world population, in different countries from 8 to 22% of the adult population aged 40 years 
and older are affected [9]. The prevalence of COPD in Europe is from 3.7 to 6.7% of the 
population and the number of relapses in patients with this disease varies from 1 to 4 times per 
year [5, 9, 20]. Morbidity and mortality rates are constantly rising. In Europe annually COPD is 
the cause of death of 200-300 thousand of people [9, 16]. In Ukraine, the death rate from COPD 
is 41.2 per 100 000 population, which is higher than the death rate from pneumonia and asthma 
[7, 8]. The high morbidity of COPD accounts for a significant economic burden on the 
economies of all countries. Thus, according to GOLD in EU annual direct costs of treating 
COPD constitute 38600000000 euro, the US, the figure is 21800000000 dollars, and indirect 
costs exceed 17 billion dollars [6, 7]. In recent decades, there is a constant increase in the 
incidence of COPD. This is due to environmental pollution, especially air, smoking and aging 
population worldwide [7, 9]. 
 Distribution of underdiagnosis of COPD, inadequate antimicrobial therapy led to an 
increase in cases of COPD with complication of bronhoectasis. Among disadvantages, attention 
should also be given tobacco smoking, which is a common risk factor for the development of 
both cardiovascular and respiratory disease [2, 7]. Significant relevance acquires polymorbidity, 
which is typical for older age groups. It was in this group of patients older than 40 years have 
seen the rapid progression of coronary artery disease (CHD). CHD is one of the leading places in 
the structure of morbidity and mortality in Ukraine. The country has about 6.8 million of patients 
with CHD. Over the past 10 years, the incidence and mortality from CHD are constantly 
increasing [1]. In view of the high prevalence of CHD and a high probability of serious 
complications that cause disability and high fatality this problem, other than medical, has a 
pronounced social character.  
It is safe to assume that during exacerbations of COPD with complication of 
bronhoectasis unlike CHD, will require a more balanced prescription. And on conservative 
treatment of severe exacerbation of COPD with complication of bronhoectasis, unlike coronary 
heart disease in the literature has been given very little attention.  
The pathogenesis is due to the activity of oxidant aggression on the mucosa of the 
respiratory tract by reactive oxygen species and other free radicals, resulting in lipid peroxidation 
and damage to biological membranes [19, 23], including immune cells. Today, more and more 
attention is paid to the immunological reactivity in patients with COPD [3]. It has been found 
that the development and exacerbation of COPD is accompanied by inhibition of a local immune 
defense against respiratory viruses and bacteria including systemic damage of cellular and 
humoral immunity [12]. There were installed systemic violations of cellular and humoral 
immunity in patients with acute exacerbation of COPD [13]. Violations of cellular immunity: 
inhibition of alveolar macrophage suppressor systems, reducing the number of T-helper cells, 
effector cytotoxic lymphocytes. With the most pronounced inhibition of T-suppressor 
lymphocytes exerted in patients receiving long-term antibiotic therapy [24]. Many infectious 
agents lead to an exacerbation of COPD, cause disturbances of mucous clearance, increased 
production of mucus thick bronchial secretions, local splitting of immunoglobulins, inhibition of 
phagocytic activity of neutrophils and alveolar macrophages, an increase in the release of 
histamine and other mediators of inflammation [3, 4]. Among the endogenous risk factors are the 
most important features of genetically caused immune reactivity. It is known that the greater 
propensity of man to infection with respiratory viruses and damage to ciliated epithelium 
determines selective IgA deficiency, and combined with a deficit of IgG [3].  
Therefore, it is necessary to prescribe for patients with acute exacerbations of COPD 
medications, providing the activation of mechanisms of self-regulation, the adequacy of the 
immune response, improving the barrier function of the bronchial mucosa. The medication 
Glutoxim is an immunoreabilitator that has immunomodulatory, bronchodilator, desensitizing, 
anti-inflammatory and antimicrobial effect. [18]. Glutoxim (registration number 98 \ 279 \ 3) – is 
chemically synthesized biologically active compound – a hexapeptide with the stabilized 
disulfide bond. Glutoxim is a representative of a new class of drug – thiopentone that has a 
modulating effect on intracellular processes, plays an important role in the regulation of 
metabolic processes in the tissues and organs, as well as in endogenous production of cytokines: 
interferons and interleukins. [10]. 
According to modern concepts, one of the leading roles in the onset and progression of 
cardiovascular diseases, (including coronary heart disease), hypertension plays the vascular 
endothelial dysfunction [25]. The vascular endothelium is the only body that regulates 
hemodynamics and perfusion according to the needs of each organ or tissue. The main role of the 
endothelium is the allocation of a number of biologically active substances. The proper 
functioning of the endothelium depends on the vascular tone (total vascular resistance, blood 
pressure), athrombogenic vascular wall, platelet activity, blood coagulation, inflammation, 
antioxidant resistance, as well as the preservation of the structural layers of the vessel wall and 
the manifestation of atherogenesis. It is likely that a violation of these regulatory actions leads to 
changes in the organs and systems that serve as the basis for the pathogenesis of many 
pathological processes, such as cardiovascular disease. Therefore, reducing damage, correction 
and maintenance of adequate functioning of the endothelium is one of the most urgent problems 
of modern therapy of vascular disease. Other drugs used in cardiology have varying degrees for 
normalizing the effect against endothelial dysfunction. One of such group of drugs is the donator 
NO, in particular L-arginine aspartate, which has positive effect in endothelial dysfunction. [14]. 
In addition, L-arginine aspartate has detoxifying, membrane stabilizing, anti-hypoxic, 
cytoprotective, antioxidant and antiradical activities. It also manifests itself as an active process 
controller of power supply and intermediary metabolism. L-arginine aspartate has a stimulating 
effect of on the activity of thymus which plays the leading role in differentiation and maturation 
of T-lymphocytes. And what is important that L-arginine aspartate promotes correction of acid-
base balance. The accumulation of data about cardiovascular and respiratory pathology changes 
the paradigms to patient’s treatment.  
The purpose of this study was to determine ways to optimize the treatment of moderate 
COPD complicated bronhoectasis on the background of CHD.  
Materials and methods.  
The study included 63 patients with COPD complicated bronhoectasis on CHD in age 
from 40 to 65 years who were hospitalized in the pulmonary department of TH №1 with 
aggravation. The average age of the patients was 52,5 ± 4,5 years. COPD diagnosis was 
established on the basis of clinical, radiological, laboratory and functional examinations in 
accordance with the orders of the Ministry of Health of Ukraine from 27.06.2013year №555 all 
patients COPD complicated by bronchiectasis, confirmed by X-rays and computed tomography. 
Investigation of pulmonary ventilation with the registration curve "flow-volume" forced 
expiratory and conduct standard bronchodilation by inhalation of salbutamol. Verify the 
diagnosis of CHD was performed according to the order of Ministry of Health of Ukraine №54 
from 14.02.2002 year. The diagnosis of ischemic heart disease was confirmed on the basis of 
standard cardiac profiles of WHO (Rose questionnaire), the nature of the changes on the 
electrocardiogram at rest according to the recommendations of the VI National Congress of 
Cardiologists of Ukraine.  
All patients were divided into 3 groups and clinical control 1 and 2 are similar in age and 
the clinical course of the disease. The control group consisted of 10 patients who received 
standard therapy with antibiotics, mucolytics within 10 days. Clinical group 1 (26 patients), 
which in addition to standard therapy was appointed Glutoxim 1ml 3% (30 mg) once a day 
intramuscular during 10 days (300 mg to 1 year), the clinical group 2 (27 patients), which in 
addition to standard therapy was appointed Glutoxim in combination with L-arginine aspartate 
4.2%, which was used intravenously in 100 ml of 1 time per day for 10 days. The volume of the 
standard therapy for patients clinical groups was the same as that of the control group. In those 
cases where the prior ambulatory patients hospitalized both groups received clinical β2-agonists 
(salmeterol, formoterol) or anticholinergics (ipratropium, tiotropium), such treatment was 
continued for the entire period of observation in a dose corresponding to the severity. The 
observation period was 14 days. 
 Immunological examination of patients was carried out in the first 3 days after admission 
and after 10 days of treatment. To which included: quantitative evaluation of T and B 
components of immunity by immunofluorescence method, counting the cell phenotype CD3+, 
CD4+, CD8+, CD16 +, CD22+ and immunoregulatory index (IRI – the ratio of 
CD4+/CD8+) [21]; study the functional activity of T-lymphocyte blast transformation via 
reaction (RBTL) [15]; performance study serum IgG, IgA, IgM [17]; determining the 
concentration of circulating immune complexes (CIC) in the average size serum [11]; study of 
phagocytic activity of neutrophils with the calculation of phagocytic index (PI) Hamburg and 
phagocytic number (FF) Wright [21].  
This study evaluated the dynamics of indicators of quality of life in COPD basic therapy 
and therapy with glutoxim connection. To study the quality of life in patients at different periods 
of exacerbation of COPD, treatment, rehabilitation using the version of the general questionnaire 
MOS SF-36 (MOS SF Item Short Form Health Survey). In order to evaluate the effect of 
treatment on quality of life of patients with COPD in addition to the questionnaire MOS SF-36 
conducted tests global assessment of the quality of care the patient and the doctor. The test 
results are evaluated by the point system. Patients self-administered questionnaire SF -36 in the 
next phase of the disease: 
1. In the beginning of the treatment at the time of admission, acute phase of the disease; 
2. In the stationary end of treatment (days 12-14); 
3. 2 months.  
Statistical processing of the results was carried out on a personal computer using a 
standard package of functions «MS Excell» and «Statistica for Windous. Release 6.0». 
Results and discussion. 
Analysis of the initial results of immunological studies showed that the patients had 
significant disorders of the immune function in cellular and humoral. The common features of 
immunological disorders in patients with COPD were in violation of humoral immunity – a 
significant decrease in levels of IgG and IgA along with the increase in the number of B-
lymphocytes (CD22+ lymphocyte population), as well as increasing the concentration of the 
CEC of medium size in the serum. Common signs of cellular immune disorders has been a 
significant decrease in the total number of subpopulations of lymphocytes and CD3+, CD4+, 
CD16+ lymphocytes. The analysis of baseline T-cell immunity in patients with COPD showed 
heterogeneity and multi-vector violations. Similar results were obtained by other researchers, and 
coincide with the literature data [13].  
Most often in patients with COPD were observed multi-vectorviolations cellular 
immunity: some observed mainly T-helper immune deficiency with low immunoregulatory 
index, in other predominantly T-suppressor immunodeficiency high immunoregulatory index. 
What can explain the different orientation of the immune response depending on the adaptive-
adaptive capabilities of a particular organism, the progression of bronchial obstruction and 
persistence of infectious and inflammatory process in the bronchial tree. Depending on these 
results all examined patients clinical groups were divided into two subgroups. The criteria for 
selection were the importance of the immunoregulatory index and type of immunodeficiency. 
Each clinical group was divided into subgroups: In subgroup A included patients with T-helper 
immune deficiency and low immunoregulatory index (in 95% of patients with IRI was within 
0.8-1.3) A.1 – 13 patients, A.2 – 12 in the subgroup included patients with T-suppressor 
immunodeficiency and high immunoregulatory index (IRI 96% of the patients ranged from 2.1-
2.6) B.1 – 13 patients B.2 – 15.  
After a 10-day treatment in patients with both clinical groups positive dynamics of 
clinical symptoms with a decrease in the intensity of dyspnae and cough, reducing the volume 
and purulence of sputum, the normalization of body temperature, improvement in general well-
being. This led to the restoration of health, or the return of health, which was before the 
escalation of the disease. Positive clinical dynamics was accompanied by improvements in 
pulmonary ventilation.  
Analysis of immunological parameters in patients in the control group showed that 
despite the advent of standard treatment, improve the immune status were observed. The total 
number of lymphocytes increased from 1,70 ± 0,14 to 1,98 ± 0,76, CD4 + - lymphocyte 0,48 ± 
0,11 to 0,46 ± 0,21, performance values were not reliable. There was a significant decrease in 
spontaneous RBTL with 0,055 ± 0,006 to 0,034 ± 0,008 (p≥0,05), although the change RBTL 
with PHA was not significant from 1,37 ± 0,11 to 1,49 ± 0,2. There was a trend to reduce the 
number of population with CD3 + 0,95 ± 0,18 to 0,84 ± 0,42, and CD8 + lymphocyte 
subpopulations with 0,41 ± 0,17 to 0,36 ± 0,22, immunoregulatory index with decreased from 
1,76 ± 0,15 to 0,51 ± 0,85, amid tendency to increase the population of lymphocytes with CD16 
+ 0,26 ± 0,10 to 0,31 ± 0,12. In humoral immunity reduction of CD22 + - lymphocytes from 0,69 
± 0,08 to 0,66 ± 0,38, as well as the content of IgG, with 8,40 ± 0,19 to 7,97 ± 0,74, IgA from 
1,31 ± 0,15 to 1,26 ± 0,22, IgM from 0,91 ± 0,06 to 0,83 ± 0,11, the number of CEC with 
61,1 ± 2,71 to 62,47 ± 4,75, all indicators were not a valid value. Phagocytic activity of 
neutrophils remained at the same level of FI with 51,0 ± 3,6 to 50,32 ± 8,31, with the FF 4,4 ± 
0,47 to 6,2 ± 3,51.  
Patients in both groups were observed clinical improvement of immune parameters. 
Patients subgroups A.1 after treatment there was a statistically significant increase in the total 
number of lymphocytes with 1,69 ± 0,15 to 2,12 ± 0,12 (p≥0,05) populations: CD3 + 
lymphocytes with 1,02 ± 0,21 to 1,50 ± 0,09 (p≥0,05), CD4 + - cells to 0,44 ± 0,13 0,78 ± 0,09 
(p≥0,05), CD16 + lymphocytes from 0,26 ± 0,05 to 0,41 ± 0,02 (p≥0,05), proliferative activity of 
lymphocytes with PHA RBTL with 1,45 ± 0,08 to 1,69 ± 0,04 (p≥ 0.05). Changes spontaneous 
RBTL with 0,055 ± 0,005 to 0,046 ± 0,004, the number of CD8 + - lymphocytes from 0,49 ± 
0,08 to 0,50 ± 0,15, did not have a valid value. This is evidence of the positive effects of 
prescribed treatment on the immune response of the body. As a result, there was a decrease 
manifestations of T-cell immunodeficiency, which was accompanied by a statistically significant 
normalization of the immunoregulatory index from 1,13 ± 0,16 to 1,83 ± 0,22 (p≥0,05). Similar 
rates of immune status were obtained in the subgroup A2 so there was an increase of the total 
number of lymphocytes to 2,19 ± 0,09 (p≥0,05) populations: CD3 + lymphocytes to 1,51 ± 0,08 
(p≥ 0,05), CD4 + - cells to 0,81 ± 0,10 (p≥0,05), CD16 + lymphocytes to 0,40 ± 0,04 (p≥0,05), 
proliferative lymphocyte activity with RBTL PHA to 1,67 ± 0,06 (p≥0,05). Changes spontaneous 
RBTL to 0,049 ± 0,006, the number of CD8 + - lymphocytes to 0,52 ± 0,11 did not have a valid 
value. This was accompanied by a statistically significant normalization of the 
immunoregulatory index to 1,83 ± 0,19 (p≥0,05).  
Patients in the clinical group B showed improvement of quantitative and functional 
characteristics of the most affected T-suppressor/cytotoxic lymphocyte subpopulations. After 
treatment in a subgroup B.1 noted a statistically significant increase in the number of 
CD3 + lymphocyte populations from 0,87 ± 0,15 to 1,27 ± 0,11 (p≥0,05) and a subset of 
CD8 + lymphocytes with 0,32 ± 0,05 to 0, 47 ± 0,03 (p≥0,05), CD16 + lymphocytes to 
0,25 ± 0,06 0,40± 0,02 (p≥0,05) that a statistically reliable normalization of the 
immunoregulatory index 2, 39 ± 0,14 to 1,85 ± 0,13 (p≥0,05). Tended to improve the functional 
activity of lymphocytes activated with PHA RBTL increase from 1,28 ± 0,14 to 1,48 ± 0,11, 
spontaneous changes RBTL with 0,054 ± 0,006 to 0,038 ± 0,009, changing the total number of 
lymphocytes with 1,71 ± 0 12 to 2,04 ± 0,17, the amount CD4 + - lymphocyte 0,51 ± 0,15 to 
0,73 ± 0,07, which did not have a valid value. A similar pattern was also observed in the 
subgroup B.2. There was a statistically significant increase in the number of CD3 + lymphocyte 
population to 1,26 ± 0,10 (p≥0,05) and a subset of CD8 + lymphocytes to 0, 49 ± 0,06 (p≥0,05), 
CD16 + lymphocytes to 0 41 ± 0,04 (p≥0,05), which was accompanied by a statistically 
significant normalization of the immunoregulatory index to 1,87 ± 0,16 (p≥0,05). Tended to 
improve the functional activity of lymphocytes with PHA RBTL increase to 1,47 ± 0,10, 
spontaneous changes RBTL to 0,039 ± 0,007, changes in the total number of lymphocytes to 
2,06 ± 0,15, the number of CD4 + - lymphocytes to 0.76 ± 0,09, which did not have a valid 
value. Registered improve the phagocytic activity of neutrophils in both clinical groups - a 
statistically significant increase in the FI and FF. So in class A.1: FI with 52,1 ± 2,7 to 64,3 ± 3,3 
(p≥0,05) FF with 4,6 ± 0,37 to 6,8 ± 0,9 (p≥0, 05), and the corresponding figures in the subgroup 
A2: PHI to 65,1 ± 3,1 (p≥0,05), the FF to 6,7 ± 0,7 (p≥0, 05) in the subgroup B.1: FI with 49,9 ± 
4,54 to 62,9 ± 4,1 (p≥0,05) FF with 4,2 ± 0,56 to 5,5 ± 0,25 (p ≥0,05), a similar pattern was also 
observed in the subgroup B.2: PHI to 61,8 ± 3,22 (p≥0,05), the FF to 5,6 ± 0,31 (p ≥0,05).  
Significantly less pronounced changes were observed in the humoral immunity of 
patients in both clinical groups. In the subgroup of A.1 tended to reduce the number of B cells: 
CD22 + lymphocyte population with 0,62 ± 0,06 to 0,53 ± 0,06, in the subgroup A2 to 0,54 ± 
0,08, although in a subset of these results were statistically significant with 0,76 ± 0,09. In the 
subgroup of B.1 to 0,48 ± 0,07 (p≥0,05) in the subgroup B.2 to 0,47 ± 0,05 (p≥0,05). In both 
clinical groups showed a statistically significant increase in serum IgA: A.1 in the subgroup with 
1,29 ± 0,14 to 1,76 ± 0,11 (p≥0,05) A.2 to 1,75 ± 0.09 (p≥0,05) in the subgroup with B.1 to 
1,33 ± 0,15 1,69 ± 0,08 (p≥0,05) B.2 to 1,71 ± 0 09 (p≥0,05). Reduction of circulating immune 
complexes in the subgroup with A.1 62,8 ± 2,72 to 56,3 ± 1,49 (p≥0,05) A.2 - up to 55,4 ± 1,45 
(p≥0, 05); B.1 in the subgroup with 59,4 ± 2,69 to 53,2 ± 1,22 (p≥0,05) B.2 - up to 52,5 ± 1,20 
(p≥0,05). This is accompanied by a tendency to a decrease of IgM and IgG content. In the 
subgroup of A.1 IgG content increased from 7,83 ± 0,21 to 8,10 ± 0,29, A.2 – up to 8,32 ± 0,28, 
in the subgroup of B.1 with 8,96 ± 0, 18 to 9,56 ± 0,15, B.2 - up to 9,57 ± 0,14. In group A, the 
content of IgM decreased from 0,88 ± 0,05 A.1 - up to 0,77 ± 0,03, A.2 – up to 0,76 ± 0,05, in 
Group B with 0,93 ± 0, 06 B.1 – up to 0,86 ± 0,04, B.2 – up to 0,87 ± 0,03, these figures were 
not reliable values. Such changes were quite expected result, given the short period of 
observation.  
In the study of quality of life of patients in both clinical groups was obtained significant 
improvement in all parameters. In the control group, significant changes were observed only in 
the index of vitality (VT). In subgroups A.1 and B.1 when connected to glutoxim therapy 
improves vitality (VT), and role functioning (RP), and physical functioning (PF) and were 
significant. In the control group, these figures did not have a valid value. To a lesser extent in the 
treatment of positive changes related to indicators of general health (GH), a clinical groups, this 
figure had reliable value. In subgroups A.2 and B.2 connection to background therapy of 
glutoxim with L-arginine aspartate led not only to significant improvement in the general 
health (GH), vitality (VT), role functioning (RP), physical functioning (PF) and the restoration of 
mental health (MH), emotional functioning (RE), which eventually led to an increase in 
viability (VT) patients. It should be noted that the improvement in these indicators is beneficial 
not only to the quality of life of patients, but also to the establishment of Compliance. Long-term 
observation showed reduction in the number of exacerbations in subgroups A.2 and B.2, which is 
possible due to the improvement of stressresistance in patients.  
Conclusions. 
Among the major disorders of T-cell immunity in COPD patients with complication of 
bronhoectasis for CHD can distinguish T cell immunodeficiency, predominantly T-helper or T-
suppressor of immune deficiency. Identified types of immunological disorders are the basis for 
immunological correction glutoxim. Use of glutoxim was effective and showed improve 
immunological parameters in patients with impaired cellular immunity.  
In addition to standard therapy glutoxim in combination with L-arginine aspartate led not 
only to an improvement in the body's immunological defense, but also to a significant 
improvement of all the parameters of quality of life. Long-term follow-up in these patients 
showed a decrease in the number of exacerbations. 
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